|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�����,��ɫ |
|
ճ�� |
|
�������� |
| ��������������� | |
|
����� |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
��������𤸽��������صĶ��������о���չ
�����, ����
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
���������һ����Ҫ�������²����ͬʱ���������������,�й��䶾�����ӵ��о������Ѿ����˴����Ĺ���.��������Ķ������Ӱ���𤸽���ӡ����������ø����ĸ��;�˿��֮���ת��������ת����.��Ҫ�����˶�������й�𤸽�����뷽��Ķ������ӷ�����о�����.
[2] Petty EM,Gibson LH,Fountain JW,Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma:implications for 9p tumor-suppressor gene(s).Am J Hum Genet,1993,53:96-104.
[3] Kamb A,Shattuck-Eidens D,Eeles R,et al.Analysis of the p16 gene(CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.Nat Genet,1994,8:23-26.
[4] Harland M,Mistry S,Bishop DT,et al.A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees.Hum Mol Genet,2001,10:2679-2686.
[5] Auroy S,Avril MF,Chompret A,et al.Sporadic multiple primary melanoma cases:CDKN2A germline mutations with a founder effect.Genes Chromosomes Cancer,2001,32:195-202.
[6] Zuo L,Weger J,Yang Q,et al.Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.Nat Genet,1996,12:97-99.
[7] Sotillo R,Garcia JF,Ortega S,et al.Invasive melanoma in Cdk4-targeted mice.Proc Natl Acad Sci U S A,2001,98:13312-13317.
[8] Eymin B,Karayan L,Seite P,et al.Human ARF binds E2F1 and inhibits its transcriptional activity.Oncogene,2001,20:1033.
[9] Rizos H,Darmanian AP,Holland EA,et al.Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF.J Biol Chem,2001,276:41424-41434.
[10] Randerson-Moor JA,Harland M,Williams S,et al.A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.Hum Mol Genet,2001,10:55-62.
[11] Kamb A,Gruis NA,Weaver-Feldhaus J,et al.A cell cycle regulator potentially involved in genesis of many tumor types.Science,1994,264:436-440.
[12] Sauter ER,Yeo UC,yon Stemm A,et al.Cyclin D1 is a candidate oncogene in cutaneous melanoma.Cancer Res,2002,62:3200.
[13] Goldstein AM,Dracopoli NC,Engelstein M,et al.Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p,and evidence for genetic heterogeneity.Am J Hum Genet,1994,54:489.
[14] Tang L,Li G,Tron VA,et al.Expression of cell cycle regulators in human cutaneous malignant melanoma.Melanoma Res,1999,9:148.
[15] Shennan MG,Badin AC,Walsh S,et al.Lack of germline CDK6mutations in familial melanoma.Oncogene,2000,19:1849-1852.
[16] Aitken J,Welch J,Duffy D,et al.CDKN2A variants in a populationbased sample of Queensland families with melanoma.J Natl Cancer Inst,1999,91:446-452.
[17] Platz A,Hansson J,Ringborg U.Screening of germline mutations in the CDK4,CDKN2C and TP53 genes in familial melanoma:a clinicbased population study.Int J Cancer,1998,78:13-15.
[18] Newton Bishop JA,Harland M,Bennett DC,et al.Mutation testing in melanoma families:INK4A,CDK4 and INK4D.Br J Cancer,1999,80:295-300.
[19] Xiong Y,Menninger J,Beach D,et al.Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins.Genomics,1992,13:575-584.
[20] Florenes VA,Faye RS,Maelandsmo GM,et al.Levels of cyclin D1 and D3 in malignant melanoma:deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma.Clin Cancer Res,2000,6:3614-3620.
[21] Abdel-Malek Z,Suzuki I,Tada A,et al.The melanocortin-1 receptor and human pigmentation.Ann N Y Acad Sci,1999,885:117.
[22] Valverde P,Healy E,Sikkink S,et al.The Asp84Glu variant of the melanocortin I receptor(MC1R) is associated with melanoma.Hum Mol Genet,1996,5:1663-1666.
[23] Palmer JS,Duffy DL,Box NF,et al.Melanocortin-1 receptor polymorphisms and risk of melanoma:is the association explained solely by pigmentation phenotype? Am J Hum Genet,2000,66:176-186.